Last updated on January 2019

Prophylactic or Preemptive Entecavir in Patients With Colorectal Cancer Who Are Inactive Hepatitis B Carriers


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Colorectal Cancer
  • Age: Between 18 - 75 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Patients with age between 18 and 75
  2. Patient with histology-proven colorectal adenocarcinoma.
  3. Patients with Eastern Cooperative Oncology Group performance status (ECOG) of 0-1
  4. Patients planned for at least 4 cycles of cytotoxic chemotherapy (either as part of curative therapy or as palliative therapy)
  5. Patients with at least 6 months' life expectancy from date of recruitment
  6. Patients with positive Hepatitis B Surface-antigen (HBsAg)
  7. Patients with normal liver function tests including alanine aminotransferase (ALT), aspartate aminotransferase alkaline (AST), phosphatase (ALP), gamma glutamyl-transpeptidase (GGT), and bilirubin
  8. Patients with negative HBV-DNA
  9. Patients with no known history of radiological &/or histological diagnosis of chronic active hepatitis or cirrhosis of any cause, or history of prior hepatitis B reactivation, or prior chronic therapy for HBV within 6 months
  10. Patients with no evidence of autoimmune hepatitis, hepatitis C or D virus infection, HIV infection or radiological evidence of liver metastasis
  11. adequate bone marrow, hepatic, and renal function within 14 days before recruitment
  12. patients who sign the informed consent
  13. Patients with good compliance during chemotherapy and follow-ups

Exclusion Criteria:

  1. Patients planned for radiation or radionuclide therapy
  2. Pregnant female patients
  3. Patients with a history of psychiatric drugs abuse and can't quit or with a mental disorder
  4. Patients with immunodeficiency, other congenital or acquired immunodeficiency, or transplantation history
  5. According to the investigators' judgment, patients with concomitant disease that seriously harms patients' safety or the completion of study.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.